Invetx, Inc.

Takeda Pharmaceutical Company Limited

Shire Human Genetic Therapies, Inc.

Madhusudan Natarajan

William Harold Brondyk

Juergen Horn

Brett Chevalier

Albert Barnes Seymour

Patrick Anthony John Haslett

Paolo G V Martini

Paolo GV Martini

Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a feline and methods of their use. The compositions involve variant feline IgG Fc regions.

Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.

Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use

The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.

Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma

Growing community of inventors

Waban, MA, United States of America

Madhusudan Natarajan